APO Research
Talk to an analyst

APO RESEARCH · REPORT

Metabotropic Glutamate Receptor 3

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Metabotropic Glutamate Receptor 3 Market Analysis and Forecast 2026-2032

19 December 2025195 pages

Choose your research edition.

Industry ResearchMetabotropic Glutamate Receptor 3 Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Metabotropic Glutamate Receptor 3 Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Metabotropic Glutamate Receptor 3 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metabotropic Glutamate Receptor 3 Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Metabotropic Glutamate Receptor 3 Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Metabotropic Glutamate Receptor 3 market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Metabotropic Glutamate Receptor 3 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Metabotropic Glutamate Receptor 3 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Metabotropic Glutamate Receptor 3 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Metabotropic Glutamate Receptor 3 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Metabotropic Glutamate Receptor 3 include Eli Lilly and Company, Prexton Therapeutics SA, Domain Therapeutics SA, Denovo Biopharma LLC, Aevi Genomic Medicine Inc and Addex Therapeutics Ltd, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Metabotropic Glutamate Receptor 3, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Metabotropic Glutamate Receptor 3, also provides the revenue of main regions and countries. Of the upcoming market potential for Metabotropic Glutamate Receptor 3, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Metabotropic Glutamate Receptor 3 revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Metabotropic Glutamate Receptor 3 market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Metabotropic Glutamate Receptor 3 revenue, projected growth trends, production technology, application and end-user industry.

Metabotropic Glutamate Receptor 3 Segment by Company

Eli Lilly and Company

Prexton Therapeutics SA

Domain Therapeutics SA

Denovo Biopharma LLC

Aevi Genomic Medicine Inc

Addex Therapeutics Ltd

Metabotropic Glutamate Receptor 3 Segment by Type

DT-010991

LY-3020371

VU-0092273

Others

Metabotropic Glutamate Receptor 3 Segment by Application

Autism

Chronic Pain

Glioma

Others

Metabotropic Glutamate Receptor 3 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metabotropic Glutamate Receptor 3 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metabotropic Glutamate Receptor 3 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metabotropic Glutamate Receptor 3.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Metabotropic Glutamate Receptor 3 in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Metabotropic Glutamate Receptor 3 company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Metabotropic Glutamate Receptor 3 revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Metabotropic Glutamate Receptor 3 Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. DT-010991 Major Player Table 3. LY-3020371 Major Player Table 4. VU-0092273 Major Player Table 5. Others Major Player Table 6. Global Metabotropic Glutamate Receptor 3 Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Autism Major Player Table 8. Chronic Pain Major Player Table 9. Glioma Major Player Table 10. Others Major Player Table 11. Metabotropic Glutamate Receptor 3 Industry Trends Table 12. Metabotropic Glutamate Receptor 3 Industry Drivers Table 13. Metabotropic Glutamate Receptor 3 Industry Opportunities and Challenges Table 14. Metabotropic Glutamate Receptor 3 Industry Restraints Table 15. Global Metabotropic Glutamate Receptor 3 Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Metabotropic Glutamate Receptor 3 Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Metabotropic Glutamate Receptor 3 Market Share by Region (2021-2026) Table 18. Global Metabotropic Glutamate Receptor 3 Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Metabotropic Glutamate Receptor 3 Market Share by Region (2027-2032) Table 20. Global Metabotropic Glutamate Receptor 3 Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Players (2021-2026) Table 22. Global Metabotropic Glutamate Receptor 3 Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Metabotropic Glutamate Receptor 3 Key Players Headquarters & Area Served Table 24. Global Metabotropic Glutamate Receptor 3 Players, Product Type & Application Table 25. Global Metabotropic Glutamate Receptor 3 Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Metabotropic Glutamate Receptor 3 by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Metabotropic Glutamate Receptor 3 Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Metabotropic Glutamate Receptor 3 Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Type (2021-2026) Table 32. Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Type (2027-2032) Table 33. Global Metabotropic Glutamate Receptor 3 Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Metabotropic Glutamate Receptor 3 Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Application (2021-2026) Table 37. Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Application (2027-2032) Table 38. Eli Lilly and Company Company Information Table 39. Eli Lilly and Company Business Overview Table 40. Eli Lilly and Company Metabotropic Glutamate Receptor 3 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Eli Lilly and Company Metabotropic Glutamate Receptor 3 Product Portfolio Table 42. Eli Lilly and Company Recent Development Table 43. Prexton Therapeutics SA Company Information Table 44. Prexton Therapeutics SA Business Overview Table 45. Prexton Therapeutics SA Metabotropic Glutamate Receptor 3 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Prexton Therapeutics SA Metabotropic Glutamate Receptor 3 Product Portfolio Table 47. Prexton Therapeutics SA Recent Development Table 48. Domain Therapeutics SA Company Information Table 49. Domain Therapeutics SA Business Overview Table 50. Domain Therapeutics SA Metabotropic Glutamate Receptor 3 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Domain Therapeutics SA Metabotropic Glutamate Receptor 3 Product Portfolio Table 52. Domain Therapeutics SA Recent Development Table 53. Denovo Biopharma LLC Company Information Table 54. Denovo Biopharma LLC Business Overview Table 55. Denovo Biopharma LLC Metabotropic Glutamate Receptor 3 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Denovo Biopharma LLC Metabotropic Glutamate Receptor 3 Product Portfolio Table 57. Denovo Biopharma LLC Recent Development Table 58. Aevi Genomic Medicine Inc Company Information Table 59. Aevi Genomic Medicine Inc Business Overview Table 60. Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 3 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 3 Product Portfolio Table 62. Aevi Genomic Medicine Inc Recent Development Table 63. Addex Therapeutics Ltd Company Information Table 64. Addex Therapeutics Ltd Business Overview Table 65. Addex Therapeutics Ltd Metabotropic Glutamate Receptor 3 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Addex Therapeutics Ltd Metabotropic Glutamate Receptor 3 Product Portfolio Table 67. Addex Therapeutics Ltd Recent Development Table 68. North America Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026) & (US$ Million) Table 69. North America Metabotropic Glutamate Receptor 3 Revenue by Type (2027-2032) & (US$ Million) Table 70. North America Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026) & (US$ Million) Table 71. North America Metabotropic Glutamate Receptor 3 Revenue by Application (2027-2032) & (US$ Million) Table 72. North America Metabotropic Glutamate Receptor 3 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 73. North America Metabotropic Glutamate Receptor 3 Revenue by Country (2021-2026) & (US$ Million) Table 74. North America Metabotropic Glutamate Receptor 3 Revenue by Country (US$ Million) & (2027-2032) Table 75. Europe Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026) & (US$ Million) Table 76. Europe Metabotropic Glutamate Receptor 3 Revenue by Type (2027-2032) & (US$ Million) Table 77. Europe Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026) & (US$ Million) Table 78. Europe Metabotropic Glutamate Receptor 3 Revenue by Application (2027-2032) & (US$ Million) Table 79. Europe Metabotropic Glutamate Receptor 3 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 80. Europe Metabotropic Glutamate Receptor 3 Revenue by Country (2021-2026) & (US$ Million) Table 81. Europe Metabotropic Glutamate Receptor 3 Revenue by Country (US$ Million) & (2027-2032) Table 82. China Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026) & (US$ Million) Table 83. China Metabotropic Glutamate Receptor 3 Revenue by Type (2027-2032) & (US$ Million) Table 84. China Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026) & (US$ Million) Table 85. China Metabotropic Glutamate Receptor 3 Revenue by Application (2027-2032) & (US$ Million) Table 86. Asia Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026) & (US$ Million) Table 87. Asia Metabotropic Glutamate Receptor 3 Revenue by Type (2027-2032) & (US$ Million) Table 88. Asia Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026) & (US$ Million) Table 89. Asia Metabotropic Glutamate Receptor 3 Revenue by Application (2027-2032) & (US$ Million) Table 90. Asia Metabotropic Glutamate Receptor 3 Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 91. Asia Metabotropic Glutamate Receptor 3 Revenue by Region (US$ Million) & (2021-2026) Table 92. Asia Metabotropic Glutamate Receptor 3 Revenue by Region (US$ Million) & (2027-2032) Table 93. SAMEA Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026) & (US$ Million) Table 94. SAMEA Metabotropic Glutamate Receptor 3 Revenue by Type (2027-2032) & (US$ Million) Table 95. SAMEA Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026) & (US$ Million) Table 96. SAMEA Metabotropic Glutamate Receptor 3 Revenue by Application (2027-2032) & (US$ Million) Table 97. SAMEA Metabotropic Glutamate Receptor 3 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 98. SAMEA Metabotropic Glutamate Receptor 3 Revenue by Country (2021-2026) & (US$ Million) Table 99. SAMEA Metabotropic Glutamate Receptor 3 Revenue by Country (US$ Million) & (2027-2032) Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. Metabotropic Glutamate Receptor 3 Image Figure 2. Global Metabotropic Glutamate Receptor 3 Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metabotropic Glutamate Receptor 3 Market Size Share 2021 VS 2025 VS 2032 Figure 4. DT-010991 Image Figure 5. LY-3020371 Image Figure 6. VU-0092273 Image Figure 7. Others Image Figure 8. Global Metabotropic Glutamate Receptor 3 Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Metabotropic Glutamate Receptor 3 Market Size Share 2021 VS 2025 VS 2032 Figure 10. Autism Image Figure 11. Chronic Pain Image Figure 12. Glioma Image Figure 13. Others Image Figure 14. Global Metabotropic Glutamate Receptor 3 Market Size (US$ Million) & (2021-2032) Figure 15. Global Metabotropic Glutamate Receptor 3 Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Metabotropic Glutamate Receptor 3 Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Metabotropic Glutamate Receptor 3 Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Metabotropic Glutamate Receptor 3 Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Metabotropic Glutamate Receptor 3 Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Type (2021-2032) Figure 22. Global Metabotropic Glutamate Receptor 3 Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Application (2021-2032) Figure 25. North America Metabotropic Glutamate Receptor 3 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Metabotropic Glutamate Receptor 3 Revenue Share by Type (2021-2032) Figure 27. North America Metabotropic Glutamate Receptor 3 Revenue Share by Application (2021-2032) Figure 28. North America Metabotropic Glutamate Receptor 3 Revenue Share by Country (2021-2032) Figure 29. United States Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Metabotropic Glutamate Receptor 3 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Metabotropic Glutamate Receptor 3 Revenue Share by Type (2021-2032) Figure 34. Europe Metabotropic Glutamate Receptor 3 Revenue Share by Application (2021-2032) Figure 35. Europe Metabotropic Glutamate Receptor 3 Revenue Share by Country (2021-2032) Figure 36. Germany Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Metabotropic Glutamate Receptor 3 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Metabotropic Glutamate Receptor 3 Revenue Share by Type (2021-2032) Figure 46. China Metabotropic Glutamate Receptor 3 Revenue Share by Application (2021-2032) Figure 47. Asia Metabotropic Glutamate Receptor 3 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Metabotropic Glutamate Receptor 3 Revenue Share by Type (2021-2032) Figure 49. Asia Metabotropic Glutamate Receptor 3 Revenue Share by Application (2021-2032) Figure 50. Asia Metabotropic Glutamate Receptor 3 Revenue Share by Region (2021-2032) Figure 51. Japan Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Metabotropic Glutamate Receptor 3 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Metabotropic Glutamate Receptor 3 Revenue Share by Type (2021-2032) Figure 59. SAMEA Metabotropic Glutamate Receptor 3 Revenue Share by Application (2021-2032) Figure 60. SAMEA Metabotropic Glutamate Receptor 3 Revenue Share by Country (2021-2032) Figure 61. Brazil Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Metabotropic Glutamate Receptor 3 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • DT-010991
  • LY-3020371
  • VU-0092273
  • Others
Applications
  • Autism
  • Chronic Pain
  • Glioma
  • Others
Companies covered
  • Eli Lilly and Company
  • Prexton Therapeutics SA
  • Domain Therapeutics SA
  • Denovo Biopharma LLC
  • Aevi Genomic Medicine Inc
  • Addex Therapeutics Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Metabotropic Glutamate Receptor 3 Market by Type
  3. 1.2.1 Global Metabotropic Glutamate Receptor 3 Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 DT-010991
  5. 1.2.3 LY-3020371
  6. 1.2.4 VU-0092273
  7. 1.2.5 Others
  8. 1.3 Metabotropic Glutamate Receptor 3 Market by Application
  9. 1.3.1 Global Metabotropic Glutamate Receptor 3 Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Autism
  11. 1.3.3 Chronic Pain
  12. 1.3.4 Glioma
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Metabotropic Glutamate Receptor 3 Market Dynamics
  1. 2.1 Metabotropic Glutamate Receptor 3 Industry Trends
  2. 2.2 Metabotropic Glutamate Receptor 3 Industry Drivers
  3. 2.3 Metabotropic Glutamate Receptor 3 Industry Opportunities and Challenges
  4. 2.4 Metabotropic Glutamate Receptor 3 Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Metabotropic Glutamate Receptor 3 Market Perspective (2021-2032)
  2. 3.2 Global Metabotropic Glutamate Receptor 3 Growth Trends by Region
  3. 3.2.1 Global Metabotropic Glutamate Receptor 3 Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Metabotropic Glutamate Receptor 3 Market Size by Region (2021-2026)
  5. 3.2.3 Global Metabotropic Glutamate Receptor 3 Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Metabotropic Glutamate Receptor 3 Revenue by Players
  2. 4.1.1 Global Metabotropic Glutamate Receptor 3 Revenue by Players (2021-2026)
  3. 4.1.2 Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Metabotropic Glutamate Receptor 3 Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Metabotropic Glutamate Receptor 3 Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Metabotropic Glutamate Receptor 3 Key Players Headquarters & Area Served
  7. 4.4 Global Metabotropic Glutamate Receptor 3 Players, Product Type & Application
  8. 4.5 Global Metabotropic Glutamate Receptor 3 Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Metabotropic Glutamate Receptor 3 Market CR5 and HHI
  11. 4.6.3 2025 Metabotropic Glutamate Receptor 3 Tier 1, Tier 2, and Tier 3
5 Metabotropic Glutamate Receptor 3 Market Size by Type
  1. 5.1 Global Metabotropic Glutamate Receptor 3 Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2032)
  3. 5.3 Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Type (2021-2032)
6 Metabotropic Glutamate Receptor 3 Market Size by Application
  1. 6.1 Global Metabotropic Glutamate Receptor 3 Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2032)
  3. 6.3 Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Eli Lilly and Company
  2. 7.1.1 Eli Lilly and Company Company Information
  3. 7.1.2 Eli Lilly and Company Business Overview
  4. 7.1.3 Eli Lilly and Company Metabotropic Glutamate Receptor 3 Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Eli Lilly and Company Metabotropic Glutamate Receptor 3 Product Portfolio
  6. 7.1.5 Eli Lilly and Company Recent Developments
  7. 7.2 Prexton Therapeutics SA
  8. 7.2.1 Prexton Therapeutics SA Company Information
  9. 7.2.2 Prexton Therapeutics SA Business Overview
  10. 7.2.3 Prexton Therapeutics SA Metabotropic Glutamate Receptor 3 Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Prexton Therapeutics SA Metabotropic Glutamate Receptor 3 Product Portfolio
  12. 7.2.5 Prexton Therapeutics SA Recent Developments
  13. 7.3 Domain Therapeutics SA
  14. 7.3.1 Domain Therapeutics SA Company Information
  15. 7.3.2 Domain Therapeutics SA Business Overview
  16. 7.3.3 Domain Therapeutics SA Metabotropic Glutamate Receptor 3 Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Domain Therapeutics SA Metabotropic Glutamate Receptor 3 Product Portfolio
  18. 7.3.5 Domain Therapeutics SA Recent Developments
  19. 7.4 Denovo Biopharma LLC
  20. 7.4.1 Denovo Biopharma LLC Company Information
  21. 7.4.2 Denovo Biopharma LLC Business Overview
  22. 7.4.3 Denovo Biopharma LLC Metabotropic Glutamate Receptor 3 Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Denovo Biopharma LLC Metabotropic Glutamate Receptor 3 Product Portfolio
  24. 7.4.5 Denovo Biopharma LLC Recent Developments
  25. 7.5 Aevi Genomic Medicine Inc
  26. 7.5.1 Aevi Genomic Medicine Inc Company Information
  27. 7.5.2 Aevi Genomic Medicine Inc Business Overview
  28. 7.5.3 Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 3 Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 3 Product Portfolio
  30. 7.5.5 Aevi Genomic Medicine Inc Recent Developments
  31. 7.6 Addex Therapeutics Ltd
  32. 7.6.1 Addex Therapeutics Ltd Company Information
  33. 7.6.2 Addex Therapeutics Ltd Business Overview
  34. 7.6.3 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 3 Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 3 Product Portfolio
  36. 7.6.5 Addex Therapeutics Ltd Recent Developments
8 North America
  1. 8.1 North America Metabotropic Glutamate Receptor 3 Revenue (2021-2032)
  2. 8.2 North America Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2032)
  3. 8.2.1 North America Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026)
  4. 8.2.2 North America Metabotropic Glutamate Receptor 3 Revenue by Type (2027-2032)
  5. 8.3 North America Metabotropic Glutamate Receptor 3 Revenue Share by Type (2021-2032)
  6. 8.4 North America Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2032)
  7. 8.4.1 North America Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026)
  8. 8.4.2 North America Metabotropic Glutamate Receptor 3 Revenue by Application (2027-2032)
  9. 8.5 North America Metabotropic Glutamate Receptor 3 Revenue Share by Application (2021-2032)
  10. 8.6 North America Metabotropic Glutamate Receptor 3 Revenue by Country
  11. 8.6.1 North America Metabotropic Glutamate Receptor 3 Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Metabotropic Glutamate Receptor 3 Revenue by Country (2021-2026)
  13. 8.6.3 North America Metabotropic Glutamate Receptor 3 Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Metabotropic Glutamate Receptor 3 Revenue (2021-2032)
  2. 9.2 Europe Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2032)
  3. 9.2.1 Europe Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026)
  4. 9.2.2 Europe Metabotropic Glutamate Receptor 3 Revenue by Type (2027-2032)
  5. 9.3 Europe Metabotropic Glutamate Receptor 3 Revenue Share by Type (2021-2032)
  6. 9.4 Europe Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2032)
  7. 9.4.1 Europe Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026)
  8. 9.4.2 Europe Metabotropic Glutamate Receptor 3 Revenue by Application (2027-2032)
  9. 9.5 Europe Metabotropic Glutamate Receptor 3 Revenue Share by Application (2021-2032)
  10. 9.6 Europe Metabotropic Glutamate Receptor 3 Revenue by Country
  11. 9.6.1 Europe Metabotropic Glutamate Receptor 3 Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Metabotropic Glutamate Receptor 3 Revenue by Country (2021-2026)
  13. 9.6.3 Europe Metabotropic Glutamate Receptor 3 Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Metabotropic Glutamate Receptor 3 Revenue (2021-2032)
  2. 10.2 China Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2032)
  3. 10.2.1 China Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026)
  4. 10.2.2 China Metabotropic Glutamate Receptor 3 Revenue by Type (2027-2032)
  5. 10.3 China Metabotropic Glutamate Receptor 3 Revenue Share by Type (2021-2032)
  6. 10.4 China Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2032)
  7. 10.4.1 China Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026)
  8. 10.4.2 China Metabotropic Glutamate Receptor 3 Revenue by Application (2027-2032)
  9. 10.5 China Metabotropic Glutamate Receptor 3 Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Metabotropic Glutamate Receptor 3 Revenue (2021-2032)
  2. 11.2 Asia Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2032)
  3. 11.2.1 Asia Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026)
  4. 11.2.2 Asia Metabotropic Glutamate Receptor 3 Revenue by Type (2027-2032)
  5. 11.3 Asia Metabotropic Glutamate Receptor 3 Revenue Share by Type (2021-2032)
  6. 11.4 Asia Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2032)
  7. 11.4.1 Asia Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026)
  8. 11.4.2 Asia Metabotropic Glutamate Receptor 3 Revenue by Application (2027-2032)
  9. 11.5 Asia Metabotropic Glutamate Receptor 3 Revenue Share by Application (2021-2032)
  10. 11.6 Asia Metabotropic Glutamate Receptor 3 Revenue by Country
  11. 11.6.1 Asia Metabotropic Glutamate Receptor 3 Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Metabotropic Glutamate Receptor 3 Revenue by Country (2021-2026)
  13. 11.6.3 Asia Metabotropic Glutamate Receptor 3 Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Metabotropic Glutamate Receptor 3 Revenue (2021-2032)
  2. 12.2 SAMEA Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Metabotropic Glutamate Receptor 3 Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Metabotropic Glutamate Receptor 3 Revenue by Type (2027-2032)
  5. 12.3 SAMEA Metabotropic Glutamate Receptor 3 Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Metabotropic Glutamate Receptor 3 Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Metabotropic Glutamate Receptor 3 Revenue by Application (2027-2032)
  9. 12.5 SAMEA Metabotropic Glutamate Receptor 3 Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Metabotropic Glutamate Receptor 3 Revenue by Country
  11. 12.6.1 SAMEA Metabotropic Glutamate Receptor 3 Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Metabotropic Glutamate Receptor 3 Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Metabotropic Glutamate Receptor 3 Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst